Abstract The sphingolipid, ceramide-1-phosphate (CIP), has been shown to promote the inflammatory phase and inhibit the proliferation and remodeling stages of wound repair via direct interaction with group IVA cytolic phospholipase A2, a regulator of eicosanoid biosynthesis that fine-tunes the behaviors of various cell types during wound healing. However, the anabolic enzyme responsible for the production of CIP that suppresses wound healing as well as bioactive eicosanoids and target receptors that drive enhanced wound remodeling have not been characterized. Herein, we determined that decreasing CIP activity via inhibitors or genetic ablation of the anabolic enzyme ceramide kinase (CERK) significantly enhanced wound healing phenotypes. Importantly, postwounding inhibition of CERK enhanced the closure rate of acute wounds, improved the quality of healing, and increased fibroblast migration via a “class switch” in the eicosanoid profile. This switch reduced pro-inflammatory prostaglandins (e.g., prostaglandin E2) and increased levels of 5-hydroxyeicosatetraenoic acid and the downstream metabolite 5-oxo-eicosatetraenoic acid (5-oxo-ETE). Moreover, dermal fibroblasts from mice with genetically ablated CERK showed enhanced wound healing markers, while blockade of the murine 5-oxo-ETE receptor (oxoeicosanoid receptor 1) inhibited the enhanced migration phenotype of these cell models. Together, these studies reinforce the vital roles eicosanoids play in the wound healing process and demonstrate a novel role for CERK-derived CIP as a negative regulator of 5-oxo-ETE biosynthesis and the activation of oxoeicosanoid receptor 1 in wound healing. These findings provide foundational preclinical results for the use of CERK inhibitors to shift the balance from inflammation to resolution and increase the wound healing rate.

Supplementary key words arachidonic acid • inflammation • eicosanoids • lipidomics • group IVA phospholipases A2 • 5-HETE • 5-oxo-ETE • ceramide-1-phosphate • ceramide kinase

The wound healing cascade is a dynamic process involving four distinct yet overlapping phases: hemostasis, inflammation, proliferation, and remodeling (1). Hemostasis is marked by vasoconstriction and the activation of clotting factors to reduce blood loss (2). Inflammation quickly follows to eliminate pathogens and external debris from the wound site (3, 4). Proliferation begins once foreign bodies have been removed by neutrophils and macrophages, allowing fibroblasts and keratinocytes to migrate into the wound site, ushering the transition from the inflammatory immune response and into the proliferative and angiogenetic phases (5). Lastly, new epithelial layers are formed, and collagen is cross-linked during the remodeling phase (6). Key factors in assessing wound maturation are the numbers and migration velocity of incoming fibroblasts, presence of fibroblast activation protein (FAP), and the deposition of collagen type I (7).

Our study focuses on the role of eicosanoids in wound healing, which are specialized lipid mediators with reported roles in mammalian wound response and the impairment of wound healing (8). For example, impaired wounds typically result from an imbalance between pro-inflammatory and anti-inflammatory eicosanoids such as prostaglandins and...
The synthesis of eicosanoids begins with the initial rate-limiting step, the generation of arachidonic acid (AA) via the activity of a phospholipase A2 (PLA2) (15). One of the major PLA2s involved in this initial step is group IVA cytosolic PLA2 (cPLA2), which our laboratory has demonstrated is activated by direct binding to the sphingolipid, ceramide-1-phosphate (C1P) (16–21). For example, siRNA technology to downregulate ceramide kinase (CERK), the enzyme responsible for C1P formation, blocked cPLA2 activation, AA release, and eicosanoid production in response to inflammatory cytokines, ATP, and calcium ionophore (16, 17).

Previous findings from the Chalfant Laboratory demonstrated that the specific interaction site for C1P is localized to the calcium binding loop II of the C2 domain of cPLA2α, specifically the cationic β-groove (19, 20). Mutagenesis of critical amino acids for CIP interaction within this site inhibited the ability of cPLA2α to translocate in response to inflammatory agonists (21). These data suggest that CERK and its product, CIP, are required for the activation of cPLA2α, and are thus major regulators of eicosanoid synthesis in cells. Our laboratory also discovered that CIP is temporally regulated, increasing in the inflammatory phase of human wound healing (22). Additional work by our laboratory has also recently shown that the CIPcPLA2α interaction negatively regulates the migration of dermal fibroblasts and 5-HETE production, and genetic ablation of this interaction enhanced acute wound healing in mice (23) (e.g., enhanced wound tensile strength, increased collagen I deposition, reduced collagen III deposition, and increased fibroblast wound infiltration).

In this study, our laboratory explored the source of CIP associated with the negative regulation of dermal fibroblast migration and wound healing. Specifically, we examined the hypothesis that inhibition of the formation of CIP via targeting the anabolic enzyme, CERK, either by genetic manipulations or by a new generation, small molecule inhibitors, will enhance the migration of murine dermal fibroblasts in culture and into the acute wounds of mice as well as induce the downregulation of PGE2 synthesis and upregulation of HETE production in murine dermal fibroblasts. Using a novel CERK inhibitor (SYR382141) in comparison to a conventional and established CERK inhibitor (N-[2-(Benzyloxyamino)-6-benzothiazolyl]tricyclo[3.3.1.13,7]decane-1-carboxamide [NVP-231]) and genetically engineered mouse models, either an ablated CIP interaction site (cPLA2α-KI) or CERK-ablated (CERK-knockout [CERK-KO]), we show that inhibition/ablation of CERK confers a distinct lipid “fingerprint” consistent with dermal fibroblasts that confers more rapid cell migration and accelerates the transition from inflammation to proliferation. In expanded mechanistic studies, a distinct role for the 5-HETE metabolite, 5-oxo-eicosatetraenoic acid (5-oxo-ETE), was shown to facilitate enhanced fibroblast migration through a murine G protein-coupled oxoicosanoid receptor (OXER1). Lastly, we found that the inhibition of CERK, postwounding, conferred enhanced wound healing and maturation providing a preclinical foundation to explore human clinical applications. Overall, these studies show that CERK-derived CIP inhibits the proliferation/remodeling stages of wound healing showing the therapeutic relevance of CERK inhibitors in this paradigm.

**MATERIALS AND METHODS**

**SYR382141 compound**

A request to access the CERK inhibitor SYR382141 should be made directly to the Neuroscience Drug Discovery Unit, Takeda California, San Diego, CA.

**PCR-based identification of WT, cPLA2α-KI, and CERK-KO**

Genotyping of WT, cPLA2α-KI, and CERK-KO mice was performed by first collecting genomic DNA using an AccuStart II genotyping kit followed by PCR as previously described (24, 25) using the following primers: KI: PLA2 58534–58556, 5′-TGGAGGTCGTGCTGTAGAGTTAG-3′; PLA2 58780–58757, 5′-TGCCAGATGTGAACCTACTCCAG-3′; KO: cre primers (5′-ATATCTCAGTACTGAGGTGGG-3′) (P1), and (5′-CCGTTTTCATATCCAGGTTACG-3′) (P2) (supplemental Fig. S1). Fifty nanograms of genomic DNA was used for each reaction along with the following primer concentrations, KI: 0.2 μmol/L PLA2 58534–58556 (P1), 0.2 μmol/L PLA2 58780–58757 (P2), and CERK-KO: 0.2 μmol/L P1 and 0.2 μmol/L P2. The following reaction cycles were repeated 33 times, 94°C for 1 min, 59°C for 1 min, and 72°C for 2 min. Reaction products expected are as follows: cPLA2α-WT: 237 bp, cPLA2α-KI: 412 bp, CERK-WT: 207, and CERK-KO: 480 bp and were examined using a 2% agarose gel.

**RT-qPCR analysis of mRNA expression**

RNA from WT and CERK-KO primary dermal fibroblasts was converted to cDNA and used for quantitative PCR analysis using primers specific to the mouse Cerk gene (Thermo)
and mouse actin control (Thermo). Methods is as previously described (26–28) (supplemental Fig. S1).

**Acute wound healing in mice**

The acute wound closure rate was examined in mice as recently reported by us (23). Specifically, a 5 mm biopsy punch was performed on the dorsum of each mouse. Silicone stints were then placed around the wound, and a combination of sutures and glue was used to hold said stints in place. Wounds were dressed using Tegaderm (3M Medical) and imaged over the course of 10 days. Wound images were analyzed using the Fiji image J bundle. Wounds were tracked as percent of initial wound size over 10 days with or without CERK inhibition via small molecule inhibitor SYR382141 or genetic ablation (CERK-KO mouse). Treatment groups (n = 5 mice/group) are as follows: untreated, carboxymethyl cellulose sham control (1% carboxymethyl cellulose), 60 mg/kg SYR382141. The sham and SYR382141 groups received an oral gavage twice a day for nine days starting on day 1.

**Histology**

Six millimeter samples of wound tissue were excised after 10 days; wounds were prepared for histological evaluation using the following procedure, as previously described (29). Excised wounds were fixed by placing them in 4% paraformaldehyde for 24 h; following fixation, the wound was placed in a cassette that allowed for the dehydration of the tissue, followed by clearing of the tissue using xylene (Fisher brand), and finally embedding the tissue in paraffin wax. Sections (5 μm) of the paraffin block were placed on clear glass slides for further treatment and staining. Staining with Masson’s trichrome and hematoxylin and eosin was performed. Rabbit polyclonal anti-FAP, alpha antibody (Abcam; ab53066; 1:100) and rabbit polyclonal anti-type I collagen (Abcam ab34710; 1:200) were used in immunohistochemical staining followed by anti-rabbit secondary antibody from Vectorstain Elite kit (VectorLabs PK-6100) and avidin-biotin complex enhancement. All sections were visualized with Vector NovaRED Chromogen kit (VectorLabs SK-4800) and counterstained with hematoxylin. Slides were viewed on Keyence BZ-X710 microscope and analyzed using the Fiji image J bundle for watershed cell counting or high-contrast stained area calculation, where appropriate.

**Isolation of mouse dermal fibroblast**

Primary mouse dermal fibroblasts (pDFs) were isolated from 10-week-old WT, CERK-KO, and cPLA2α-KI BALB/c males as previously described (30). Once harvested, cells were cultured using high glucose DMEM (Gibco) supplemented with 20% FBS (Gibco) and 2% penicillin/streptomycin (Bio Whittaker) at standard incubation conditions. Cells were not used after passage 5.

**Scratch-induced mechanical trauma of fibroblasts**

pDFs obtained from WT, CERK-KO, and cPLA2α-KI mice were plated at a density of 2 × 10^5 on 100 mm tissue culture plates in high glucose DMEM supplemented with 10% FBS (Gibco) and 2% penicillin/streptomycin (Bio Whittaker) and left overnight to adhere at standard incubation conditions. Following the overnight incubation, cells were rested in 2% FBS (Gibco), 2% penicillin/streptomycin (Bio Whittaker), and high glucose DMEM (Gibco) for 2 h. After the 2 h resting period, mechanical trauma was induced on the monolayer by performing scratches across the diameter of the plate in an asterisk pattern using four 20 μl pipette tips on a multichannel micropipette. Media were taken for lipidomic analysis at multiple time points (0 h and 2 h).

**Exogenous addition of CERK inhibitors to human umbilical vein endothelial cells and human leukemia 60 cells**

Human umbilical vein endothelial cells (HUVECs) were plated at a density of 2 × 10^5 cells in a 6-well plate containing endothelial cell growth medium-2 with BulletKit supplements (Lonza; catalog no: CC-3162) and allowed to rest overnight. Human leukemia (HL) 60 cells were plated at a density of 1 × 10^6 cells in 100 mm tissue culture plates containing Iscove’s Modified Dulbecco’s Medium (ThermoFisher; catalog no: 12200036) with 10% FBS (Gibco). After the resting period, media were aspirated and replaced with new growth media containing the addition of inhibitors (100 nM SYR382141, 300 nM NVP-231, or 0.001% DMSO control) and allowed to rest for another 24 h before media and cell lysate collection for lipid analysis, as previously described (31).

**Analysis of eicosanoids by ultra performance liquid chromatography ESI-MS/MS**

Eicosanoids were separated using a Shimadzu Nexera X2 LC-30AD coupled to a SIL-30AC auto injector, coupled to a DGU-20A5R degassing unit in the following way as previously described (32). A 14 min reversed phase LC method utilizing an Ascentis Express C18 column (150 mm × 2.1 mm, 2.7 μm) was used to separate the eicosanoids at a 0.5 ml/min flow rate at 40°C as previously described by us (33–35). The column was equilibrated with 100% solvent A [acetonitrile:water:formic acid (20:80:0.02, v/v/v)] for 5 min and then 10 μl of sample was injected. Hundred percent solvent A was used for the first two minutes of elution. Solvent B [acetonitrile/isopropanol/formic acid (20:80:0.02, v/v/v)] was increased in a linear gradient to 25% solvent B at 3 min, to 30% at 6 min, to 55% at 6.1 min, to 70% at 10 min, and to 100% at 10.10 min. Hundred percent solvent B was held constant until 13.0 min, where it was decreased to 0% solvent B and 100% solvent A from 13.0 min to 13.1 min. From 13.1 min to 14.0 min, solvent A was held constant at 100%. Eicosanoids were analyzed via MS using an AB Sciex Triple Quad 5500 mass spectrometer as previously described (36). Q1 and Q3 were set to detect distinctive precursor and product ion pairs. Ions were fragmented in Q2 using N2 gas for collisionally induced dissociation. Analysis used multiple reaction monitoring in negative ion mode. Eicosanoids were monitored using precursor → product MRM pairs. The mass spectrometer parameters were as previously described (37, 38): curtain gas: 20; collisionally activated dissociation: medium; ion spray voltage: -4500 v; temperature: 300°C; gas 1: 40; gas 2: 60; declustering potential; collision energy; and cell exit potential vary per transition.

**Migration analysis of fibroblasts**

Cells were seeded into 24-well tissue culture plates at a density of 7.5 × 10^4 and allowed to grow to confluence. Once a confluent monolayer was achieved, cells were placed in 2%
concentrations. Addition of various eicosanoids at the aforementioned and high glucose DMEM media (Gibco) containing the and the media were exchanged with fresh 2% FBS (Gibco) high glucose DMEM media (Gibco) containing the addition of various eicosanoids and/or inhibitors at the following concentrations (1.0 nM 5-HETE, 1.0 nM 5-oxo-ETE, 0.2 nM MK886, 10 μM Guel654, 100 nM SYR382141, 100 nM NVP-231) and allowed to rest. After the 2 h resting period, mechanical trauma was induced on the a confluent monolayer was achieved, cells were placed in 2% FBS (Gibco)/2% penicillin/streptomycin (Bio Whittaker) high glucose DMEM media and allowed to rest for 2 h. After the 2 h resting period, mechanical trauma was induced on the monolayer by performing a single scratch across the diameter of each well using a 20 μl pipette tip. Cells were observed using a live cell incubation chamber maintained at 37°C in a 95% air/5% CO2 atmosphere mounted on a Keyence BZ-X710 microscope, which took images every 3 min for 24 h. Migration velocity was calculated using the Keyence VV-9000 motion analysis software as previously described (23).

Exogenous addition of eicosanoids/inhibitors on dermal fibroblasts

pDFs were seeded into 24-well tissue culture plates at a density of 7.5 x 10^4 and allowed to grow to confluence. Once a confluent monolayer was achieved, cells were placed in 2% FBS (Gibco) high glucose DMEM media (Gibco) containing the addition of various eicosanoids and/or inhibitors at the following concentrations (1.0 nM 5-HETE, 1.0 nM 5-oxo-ETE, 7.5 nM MK886, 10 μM Guel654, 100 nM SYR382141, 100 nM NVP-231) and allowed to rest. After the 2 h resting period, mechanical trauma was applied as mentioned previously, and the media were exchanged with fresh 2% FBS (Gibco) and high glucose DMEM media (Gibco) containing the addition of various eicosanoids at the aforementioned concentrations.

Statistical analysis

Graphing and statistics were performed using Prism GraphPad (Prism Software, San Diego, CA). Data were analyzed via ANOVA followed by Tukey’s post hoc test or Dunnnett’s multiple comparisons test where applicable. All data were reported as mean ± standard deviation (SD); P < 0.05 was considered statistically significant.

Ethical considerations

All mouse studies were undertaken under the supervision and approval of the USF IACUC (Protocol# IS00004094 and IS00004110) following standards set by the Federal and State government. USF is fully accredited by AAALAC International as program #000434.

RESULTS

SYR382141 inhibits CIP production in multiple cell types

Previously, our laboratory reported that the interaction of CIP and group IVA PLA2 was a negative regulator of acute wound healing and the migration of dermal fibroblasts, but the source of CIP was not known. To examine the source of CIP for these phenotypes, we obtained a new generation inhibitor of one known source of mammalian CIP, CERK, which was developed by Takeda Corporation and designated SYR382141 and evaluated via previously described analyses (39–45). This compound inhibited CERK activity in vitro with an IC50 of 5 nM for human CERK and 9 nM for mouse CERK. SYR382141 did not significantly affect the activity of closely related kinases such as sphingosine kinase 1 and 2 (>100 μM, supplemental Table S1) as well as kinases in a global kinase panel (1 μM; supplemental Table S1). SYR382141 also demonstrated an IC50 of >30 μM to induce cytotoxicity in tissue culture (supplemental Table S1). To evaluate the ability of SYR382141 to inhibit CERK-derived CIP production in cells, pDFs and HUVECs were treated with SYR382141 or the positive control, the CERK inhibitor NVP-231, and analyzed via ultra performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry (22, 36) (Fig. 1). The levels of detectable CIP species, D-e-C16:0 CIP (C16:0), D-e-C14:0 CIP (C14:0), D-e-C24:0 CIP (C24:0), and D-e-C24:1 CIP (C24:1) were significantly reduced by SYR382141 in pDFs to an equivalent or greater extent as NVP-231 (17) using nanomolar concentrations (Fig. 1A). Similar results were observed in HUVECs (Fig. 1B). Pharmacokinetically, SYR382141 treatment of mice demonstrated significant plasma concentrations over 4 h, which would allow for initial preclinical studies on the effectiveness of inhibiting CERK inhibition in modulation of the in vivo phenotype, acute wound healing (supplemental Table S2). These data demonstrate that nanomolar concentrations of SYR382141 significantly block the production of CERK-derived CIP in cells analogous to an established inhibitor of the enzyme, but importantly, SYR382141 can be utilized to inhibit CERK in mice.

CERK inhibition and genetic ablation improves wound closure rate and healing quality in vivo

To determine whether CERK inhibitors could recapitulate the enhanced wound healing observed in a genetically engineered mouse model where the CIP binding site in cPLA2α was ablated (cPLA2α KO mice; KI) (23), WT mice were subjected to an acute excisional wound. One day post-wounding, WT mice were treated twice daily, orally with the new generation CERK inhibitor, SYR382141, versus the control (sham) and untreated mice. The dose of SYR382141 utilized showed significant levels of the drug in mouse tissues (e.g., kidney) (supplemental Table S3), and importantly, a significant increase in the rate of wound closure was observed after 10 days (Fig. 2). CERK inhibition dramatically increased the presence of FAP and subsequent pDFs in the acute wounds at 10 days (Fig. 3). Furthermore, both the Masson’s trichrome stain and immunohistochemistry analysis for type I collagen staining indicate enhanced collagen type I deposition. To confirm the specificity of the effect of SYR382141 via CERK inhibition, a novel CERK-KO mouse was examined in the same context, but in the absence of SYR382141 treatment (supplemental Fig. S1), which also showed a significant increase in the rate of wound closure at days 6–10 (Fig. 2) as well as enhanced pDFs (FAP staining) and collagen type 1 in the wounds (Fig. 3). These data indicate that CIP derived from
CERK acts as a negative regulator of fibroblast migration into the wound environment, and inhibition or genetic ablation of CERK significantly enhances acute wound healing and maturation. Furthermore, inhibition of CERK is beneficial to acute wound healing in a post-wounding manner.

CERK inhibition enhances dermal fibroblast migration

To examine specific mechanisms that may contribute to an improved wound healing rate, pDFs were cultured ex vivo from WT and homozygous CERK-KO (CERK<sup>−/−</sup>; CERK-KO) mice along with a positive control, pDFs cultured from homozygous cPLA<sub>α</sub> knockin mice with the CIP interaction site ablated (cPLA<sub>α</sub> KI) (23). As previously reported (23), cPLA<sub>α</sub>-KI fibroblasts migrated more rapidly than WT (Fig. 4A, B). The same increase in migration velocity was also observed for WT pDFs with inhibition of CERK using SYR382141 or the CERK inhibitor, NVP-231, versus sham controls (Fig. 4A, B). Additionally, pDFs from mice with CERK genetically ablated (CERK-KO), which produce a similar reduction in CIP to SYR382141-treated pDFs (Fig. 4C), also showed a similar migration velocity profile to that of SYR382141-treated WT and cPLA<sub>α</sub>-KI fibroblasts (Fig. 4A, B). Also of note, addition of SYR382141 or NVP-231 was unable to further enhance the migration velocities of cPLA<sub>α</sub>-KI or CERK-KO pDFs (Fig. 4B). Lipidomic analysis of SYR382141-treated WT pDFs as well as CERK KO pDFs after mechanical trauma showed significant increases in multiple LOX-derived

Fig. 1. SYR382141 decreases ceramide-1-phosphate levels in cells. A: WT pDFs pretreated with SYR382141 (100 nM), NVP-231 (100 nM), or DMSO (0.01%) for 30 min received mechanical trauma via asterisk pattern scratch across the plate. Cells were collected 2 h post-injury and analyzed for CIP levels via UPLC ESI-MS/MS. Values expressed as fold change to DMSO controls (*P < 0.05, **P < 0.01, ***P < 0.001; n = 3, pDFs collected from three different mice; two-way ANOVA with Dunnett's multiple comparisons test). B: HUVECs were treated with SYR382141 (100 nM), NVP-231 (300 nM), or DMSO (0.01%) for 24 h. Cells were collected and analyzed for CIP levels via UPLC ESI-MS/MS. Values expressed as fold change to DMSO controls (*P < 0.05, **P < 0.01, ***P < 0.001; n = 3; one-way ANOVA with Tukey post-hoc test).
HETE species (e.g., 5-HETE, 12-HETE, 15-HETE), and the more bioactive metabolite of 5-HETE, 5-oxo-ETE, and the pro-inflammatory prostaglandin, PGE2, trended downward (Fig. 4D). Changes in 5-HETE and 5-oxo-ETE production became evident as early as 60 min postinjury, but no changes in the levels of the CERK substrate, ceramide, were observed (supplemental Fig. S3A, B). Similar eicosanoid profiles were observed in HUVECs and HL-60 cells treated with NVP-231 (supplemental Fig. S2). Lipidomic analysis of wound tissue from healed wounds in SYR382141-treated mice displayed significant increases in 5-HETE and 5-oxo-ETE but did not show the reduced PGE2 levels observed in pDFs treated with CERK inhibitors (Fig. 5). These data demonstrate that C1P derived from the anabolic enzyme, CERK, is a negative regulator of 5-oxo-ETE biosynthesis and pDF migration via direct association with cPLA2α.

Enhanced dermal fibroblast migration requires 5-HETE/5-oxo-ETE signaling via an OXER1-like receptor

To determine whether the 5-HETE/5-oxo-ETE derived via the 5-LOX/5-lipoxygenase-activating protein pathway drives pDF migration in a paracrine/autocrine manner, we employed the 5-lipoxygenase-activating protein inhibitor MK886 to prevent 5-HETE/5-oxo-ETE production and Gue1654, a non-Gαi-biased antagonist of human OXER1, which blocks 5-oxo-ETE-triggered functional events (46). MK886 and Guel564 effectively reduced cPLA2α KI and CERK-KO pDF migration velocity to that of WT pDFs and blocked SYR382141 effects on the WT pDFs (Fig. 6). A combination of MK886 and Guel564 did not act additively or synergistically to block the effect of the genetic ablation of the C1P/cPLA2α interaction or CERK inhibition. These data demonstrate that 5-HETE/5-oxo-ETE drive

Fig. 2. Inhibition of ceramide kinase increases the closure rate of acute wounds in mice. A: Wound closure rate of 5 mm biopsy wound on dorsum of CERK-KO or WT mice treated with carboxymethyl cellulose (CMC) control (1% CMC) or SYR382141 (60 mg/kg), orally twice daily beginning 1 day post-injury (1 wound per mouse repeated on two separate occasions). B: Graph depicting acute wound closure rate quantified as percent of initial wound size over 10 days. Two-way ANOVA with Dunnett's multiple comparisons test, *P < 0.05, ****P < 0.0001; n = 5 wounds per genotype, 1 per mouse.
DISCUSSION

In this study, we characterized both a new *CERK*-KO mouse and a new small molecule inhibitor of CERK in the context of an enhanced wound healing phenotype. Specifically, we showed that inhibition of CERK-derived C1P could recapitulate the finding that genetic ablation of the C1P/cPLA2α interaction site enhances acute wound healing through increased dermal fibroblast migration and accelerated type I collagen deposition characteristic of nonfibrotic healed wounds (22). In this regard, CERK ablation or inhibition with this novel compound did recapitulate enhanced acute wound healing, and importantly, this effect occurred

Fig. 3. Inhibition and genetic ablation of ceramide kinase improve wound quality. A: Wound tissue harvested 10 days post-injury from WT control (1% CMC), *CERK*-KO, and SYR382141-treated (60 mg/kg) WT mice under H&E (cell infiltration), Masson’s Trichrome (collagen deposition), FAP (fibroblast activation protein), and type I collagen staining. B: Graph depicting quantification of infiltrating cells, FAP area, and type I collagen area, analyzed via ImageJ cell counter and Fiji ImageJ bundle area tool, contrast enhanced (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001; n = 3 samples per treatment group, 1 wound per mouse; two-way ANOVA with Dunnett’s multiple comparisons test).
post-wounding and thus sets the foundational preclinical studies to move forward for future clinical efficacy studies. Furthermore, this study determines the source of C1P activating cPLA2α signaling in suppressing dermal fibroblast migration and wound maturation as CERK versus another means of C1P biosynthesis like the reported mammalian S1P acylase activity (47).

This study also expanded the mechanistic knowledge as to how the association of CERK-derived C1P with cPLA2α drives enhanced wound healing, wound maturation, and pDF migration/collagen deposition. More specifically, this study demonstrated that CERK-derived C1P negatively regulates 5-HETE biosynthesis with 5-HETE, but also showed that 5-HETE was metabolized to 5-oxo-ETE, which is 100-fold more biologically active. This 5-HETE metabolite was found to act in an autocrine/paracrine manner by activating a murine OXER1 receptor to enhance pDF migration.

Fig. 4. Inhibition or genetic ablation of ceramide kinase enhances the migration of dermal fibroblasts and HETE biosynthesis. A: pDFs from WT, CERK-KO, and cPLA2α-KI mice treated with DMSO (0.001%), SYR382141 (100 nM) or NVP-231 (100 nM). Still images from time points 0- and 24-h. Brightness enhanced; lines added for emphasis. Cells were observed using a live cell incubation chamber mounted on a Keyence BZ-X710 microscope which took images every 3 min for 24 h (n = 4; pDFs taken from two separate animals per genotype). B: Graph depicting migration velocities of pDFs treated with CERK inhibitors SYR382141 (100 nM) or NVP-231 (100 nM), calculated using the Keyence VW-9000 motion analysis software (Dunnett’s multiple comparisons test; n = 4; pDFs taken from two separate animals per genotype). C: C1P (C16 (C16:0) and C24 (C24:0)) production in wound tissue from CERK-KO mice compared to WT (n = 4 per genotype; one wound per mouse). D: Eicosanoids from WT, CERK-KO, and cPLA2α-KI pDFs pretreated with SYR382141 or DMSO control collected 2 h after mechanical injury (two-way ANOVA with Dunnett’s multiple comparisons test; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001; n = 3, pDFs taken from three separate mice per genotype).
The murine OXER1 receptor has yet to be defined unlike the homolog to the human OXER1 receptor. Regardless, the effectiveness of the OXER1 antagonist, Gue1654, which blocks both 5-HETE and 5-oxo-ETE effects on pDF migration, shows the existence of an undefined homolog of the human OXER1. A recent report by Lai et al. (48) also demonstrates that the uncharacterized murine OXER1 receptor does exist in mice due to successful treatment with Gue1654 affecting coronary artery ligation-induced ischemic myocardial injury. Homology analysis shows that the mouse hydroxycarboxylic acid receptor 2 (HCAR2), which has been proposed to mediate 5-oxo-ETE responses in mice (49) and shares approximately 42% homology with human OXER1, is highly expressed in adipose tissue and macrophages and is expressed 3- to 5-fold higher when exposed to inflammatory mediators (e.g., lipopolysaccharide, tumor necrosis factor α, interleukin 1) (50). However, future studies need to confirm this murine receptor as the target for Gue1654 in mice to block 5-HETE and 5-oxo-ETE biological responses. Preliminary studies from our group utilizing compounds reported to nonspecifically downregulate murine HCAR2 in pDFs show similar migration inhibition effects as Gue1654 supporting the hypothesis that HCAR2 is the 5-oxo-ETE receptor in mice. Overall, this study can conclude that an OXER1 G-protein-coupled receptor exists in mice, which is required for 5-HETE and 5-oxo-ETE to enhance pDF migration, but this study cannot confirm the exact receptor homolog to human OXER1 at this time.

Notably, both the loss of C1P/cPLA2α interaction and the inhibition of CERK resulted in dramatic decrease of inflammatory prostaglandins concomitant with 5-HETE increase. Indeed, CIP reportedly increases during the inflammatory stage of wound healing in mice (Fig. 7). The murine OXER1 receptor has yet to be defined unlike the homolog to the human OXER1 receptor. Regardless, the effectiveness of the OXER1 antagonist, Gue1654, which blocks both 5-HETE and 5-oxo-ETE effects on pDF migration, shows the existence of an undefined homolog of the human OXER1. A recent report by Lai et al. (48) also demonstrates that the uncharacterized murine OXER1 receptor does exist in mice due to successful treatment with Gue1654 affecting coronary artery ligation-induced ischemic myocardial injury. Homology analysis shows that the mouse hydroxycarboxylic acid receptor 2 (HCAR2), which has been proposed to mediate 5-oxo-ETE responses in mice (49) and shares approximately 42% homology with human OXER1, is highly expressed in adipose tissue and macrophages and is expressed 3- to 5-fold higher when exposed to inflammatory mediators (e.g., lipopolysaccharide, tumor necrosis factor α, interleukin 1) (50). However, future studies need to confirm this murine receptor as the target for Gue1654 in mice to block 5-HETE and 5-oxo-ETE biological responses. Preliminary studies from our group utilizing compounds reported to nonspecifically downregulate murine HCAR2 in pDFs show similar migration inhibition effects as Gue1654 supporting the hypothesis that HCAR2 is the 5-oxo-ETE receptor in mice. Overall, this study can conclude that an OXER1 G-protein-coupled receptor exists in mice, which is required for 5-HETE and 5-oxo-ETE to enhance pDF migration, but this study cannot confirm the exact receptor homolog to human OXER1 at this time.

Notably, both the loss of C1P/cPLA2α interaction and the inhibition of CERK resulted in dramatic decrease of inflammatory prostaglandins concomitant with 5-HETE increase. Indeed, CIP reportedly increases during the inflammatory stage of wound healing in mice.
human subjects but then decreases during the proliferation and remodeling stages (51). These findings, when coupled with CIP being a negative regulator of proliferation and wound maturation (23), suggest that CIP is a pro-inflammatory mediator modulating the inflammatory stage and an essential “stop-gap” in the subsequent activation of the proliferation stage. Thus, blocking CIP production or CIP interaction with cPLA₂α proves to be beneficial for condensing the inflammatory phase and inducing the proliferation/remodeling phases earlier by enhancing fibroblast activity. Interestingly, CERK inhibitors also increased

Fig. 6. A: Graph depicting pDF migration velocity of WT, CERK-KO, and cPLA₂α-KI pDFs treated with combinations of FLAP inhibitor MK886 (7.5 nM), OXER1 antagonist Gue1654 (10 μM), ceramide kinase inhibitor SYR382141 (100 nM). All values compared to WT DMSO control (n = 3 per treatment; pDFs taken from three separate mice per genotype; two-way ANOVA with Dunnett’s multiple comparisons test; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001). B: Graph depicting pDF migration velocity of WT, CERK-KO, and cPLA₂α-KI pDFs treated with combinations of 5-HETE (100 nM), and 5-oxo-ETE (1 nM) treatments in combination with MK886 (7.5 nM) and Gue1654 (10 μM). All values compared to panel (A) WT DMSO control (n = 3 per treatment; pDFs taken from three separate mice per genotype; two-way ANOVA with Dunnett’s multiple comparisons test; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001). C: Representative microscope images of 5-oxo-ETE rescue and Gue1654 suppression of pDF migration from data graphed in panels A and B. Contrast enhanced, lines added for emphasis.
other proresolution 15-LOX-derived eicosanoids such as 15-HETE and RVD$_{1}$ in various cell types. These data further suggest that CIP may regulate additional PLA$_{2}$ isoforms, which regulate the production of these specific eicosanoids. One possibility could be cPLA$_{2\beta}$, which has not been well characterized and contains a C2-domain analogous to cPLA$_{2\alpha}$ (52, 53).

One conundrum from our study is the observation that inhibition of CIP improves pDF migration. Although congruent with our previous finding in mouse embryonic fibroblasts with CERK ablated, other laboratories have reported that CIP treatment induces cellular migration in macrophages (54) and pancreatic cells (55). We hypothesize that these differences may be due to the cellular localization of CIP. For instance, exogenous CIP treatment using a vesicle-based delivery mainly increases the CIP content of the plasma membrane (PM) in various cell types (56) with rapid metabolism to ceramide observed (36). This PM pool of CIP may encourage migration via association with factors such as annexins (32). Additionally, the reported opposing functions of CIP on cell migration may be due to cell type–specific variances as in our studies. Indeed, our studies utilize fibroblasts, whereas other reports show that CIP enhances macrophage migration (54). Inhibition of CIP may reduce macrophage-induced inflammation in the wound, which is a plausible mechanism to accelerate dermal wound healing. Our current study argues against a cell type–specific variance as we show that both HUVECs and HL-60 cells increase 5-HETE and 5-oxo-ETE in response to CERK inhibition, and thus, any context variations are likely due to differences in OXER1 activation in specific cell types.

Metabolism to other sphingolipids that drive cellular migration may also be a plausible explanation for the differential reports on CIP in cell migration (e.g., catabolism to sphingosine-1-phosphate) (57). Furthermore, an additional anabolic pathway for CIP generation does exist in mammalian cells, which may involve an sphingosine-1-phosphate-acylase (47) at the PM. CERK-derived CIP is more recognized as a Golgi form of CIP (58) and associated with cPLA$_{2\alpha}$ activation and eicosanoid biosynthesis. The form of CIP may inhibit migration due to association with cPLA$_{2\alpha}$ localized to this organelle and modulation of specific eicosanoids (e.g., PGE$_{2}$) (58). Additionally, transport of CIP to the PM by CIP transport protein (CPTP) remains a plausible regulatory mechanism between Golgi-CIP blocking migration and PM-CIP enhancing migration or by limiting CIP release for paracrine effects (59, 60). CERK regulation and CIP anabolism are still an enigma in the field, which was mainly due to a lack of sensitive techniques to consistently measure CIP levels accurately in cells. Although this issue is now rectified, CIP biosynthesis has not been strongly revisited. Originally, due to the very low levels of CIP in the cells versus the substrate of CERK, ceramide, conversion to CIP was not considered a plausible cellular “rheostat” for reducing ceramide levels to block proapoptotic mechanisms. The discovery of the CPTP in 2013 dispelled that dogma as these studies found a high level of “flux” of ceramide through CERK in some cell types, which was rapidly transported from the Golgi to other cellular organelles and catabolized (39). In this study, no increases in ceramides in the time frame (60 min) that CIP increases by ~2-fold was observed. Inhibition of CERK caused a marked trend in the increase of ceramide levels after mechanical trauma to cells in culture, but these differences were not significant suggesting either CERK activation or CPTP inhibition/downregulation is the mechanism of CIP induction. Nonetheless, the unique functions for specific CIP anabolic pathways require further study to elucidate their specific cellular roles, which may be opposing depending on the topology of the CIP production or cell type–specific. With recent advances in examining metabolic “flux” of sphingolipids via mass spectrometry, the regulatory mechanisms for CIP biosynthesis can be explored in the future in detail.

One of the more important outcomes of this study is the demonstration of rapid acute wound closure from CIP inhibition in vivo in a postwounding manner. Thus, topical treatment of wounds with a CERK inhibitor could be effective in enhancing wound healing and possibly even incorporated into antibiotic ointments in future studies. One of the unique strengths of SYR382141 is its ability to significantly reduce CIP levels in vivo. Additionally, CERK inhibiting drugs may also
be adaptable to chronic wounds, which fail to resolve and are “stalled” in the inflammatory stage possibly due to continued CIP production, high PGE2 (61), and elevated neutrophil activity (62). Indeed, the main component of the venom of the Brown Recluse spider (63) is sphingomyelinase D (SMase D), which hydrolyzes sphingomyelin to CIP. The dermal necrosis/ulceration induced by SMase D is well documented in patients bitten by the Brown Recluse spider (64), which presents as ulcerative wound similar in many aspects to a pressure ulcer. Thus, the chronic synthesis of CIP would be a plausible driver of “stalled” wound healing. CERK inhibitors may have the ability to suppress the synthesis of CIP as well as PGE2 (65), enhance 5-HETE and 5-oxo-ETE production, and induce fibroblast activation, thus promoting wound healing of stall wounds linked to neutrophilia and a chronic inflammatory stage. On the other hand, some pathogenic bacteria also have SMase D (66, 67), which may stall wound healing independent of CERK, and thus, a combination therapy of 5-oxo-ETE and CERK inhibitors may provide more benefit in a clinical setting where the wound microbiome is also a major factor in wound healing outcomes. Lastly, a better mechanistic understanding of the CERK/5-oxo-ETE interplay could be valuable for treating other diseases highly correlated to these lipid biomarkers such as preeclampsia (68, 69) and type 1 diabetes (70, 71).

In conclusion, this study demonstrates that enhanced wound healing and maturation is induced by blocking CERK-derived CIP, which is a negative regulator of fibroblast function and the 5-HETE/5-oxo-ETE/OXER1 axis. Our findings show the importance of sphingolipids and resulting eicosanoids in the wound healing process and provide the groundwork for foundational preclinical studies to move forward for future clinical therapeutic development of CERK inhibiting drugs that accelerate the healing rate and closure of wounds, especially for postinjury treatment.

Data availability
All data are contained within the manuscript.

Supplemental data
This article contains supplemental data (72–80).

Acknowledgments
We would like to thank the Neuroscience Drug Discovery Unit, Takeda California, San Diego, CA, for their provision of the new ceramide kinase inhibitor, SYR382141, to test in our mouse models of wound healing.

Author contributions
K. D. M., D. J. S., H. P. M., H.-J. H., J. S., M. K., R. F. D., and C. E. C. conceptualization; H. P. M., H.-J. H., J. S., M. K., R. F. D., and C. E. C. methodology; A. N. A., H. P. M. M. K., and C. E. C. validation; K. D. M., D. J. S., H. P. M., A. N. A., and M. K. formal analysis; K. D. M., D. J. S., H.-J. H., and M. K. investigation; H.-J. H. and J. S. resources; K. D. M., D. J. S., and A. N. A. data curation; K. D. M. and D. J. S. writing - original draft; R. F. D. and C. E. C. writing - review & editing; M. K., R. F. D., and C. E. C. supervision, C. E. C. project administration; J. S. and C. E. C. funding acquisition.

Author ORCIDs
Kenneth D. Maus https://orcid.org/0000-0002-8688-2934
Henry Patrick MacKnight https://orcid.org/0000-0003-3292-6155
Minjung Kim https://orcid.org/0000-0002-5682-6640
Charles E. Chalfant https://orcid.org/0000-0002-5844-5235

Funding and additional information
This work was supported by research grants from Takeda Corporation (C. E. C); the Veteran’s Administration (VA Merit Review, I BX001792) (C. E. C); and a Research Career Scientist Award, IK6BX004603 (C. E. C); the National Institutes of Health via R01s AI139072 (C. E. C), GM137578 (C. E. C), DK126444 (C. E. C), and GM137394 (C. E. C). The CERK knockout mouse was created using funds from the Paul M. Corman, M. D. Endowed Chair in Cancer Research held by CEC when located at Virginia Commonwealth University, Richmond, VA. The contents of this manuscript do not represent the views of the Department of Veterans Affairs or the United States Government. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Conflict of interest
The authors declare that they have no conflicts of interest with the contents of this article.

Abbreviations
5-oxo-ETE, 5-Oxo-eicosatetraenoic acid; AA, arachidonic acid; CIP, ceramide-1-phosphate; CERK, ceramide kinase; CERK-KO, CERK-knockout; cPLA₂α, cytosolic phospholipase A₂ alpha; CPTP, C1P transport protein; COX, cyclooxygenase; EGF, epidermal growth factor; FAP, fibroblast activation protein; FLAP, 5-lipoxigenase-activating protein; HUVEC, human umbilical vein endothelial cell; LOX, lipoxygenase; NVP-231, N-[2-(Benzoxyamino)-6-benzothiazolyl]-tricyclo[3.3.1.13,7]decane-1-carboxamide; OXER1, oxoeicosa-noid receptor 1; pDFs, primary dermal fibroblasts; PGE₂, prostaglandin E₂; PM, plasma membrane.

Manuscript received November 9, 2021, and in revised form February 18, 2022. Published, JLR Papers in Press, February 24, 2022, https://doi.org/10.1016/j.jlr.2022.100187

REFERENCES
1. Clark, R. A. F. (1988) Wound repair. In The Molecular and Cellular Biology of Wound Repair. R. A. F. Clark, editor. Springer, Boston, MA, 3–50
2. Versteeg, H. H., Heemskerk, J. W. M., Levi, M., and Reitsma, P. H. (2013) New fundamentals in hemostasis. Physiol. Rev. 93, 327–358
3. Diegelmann, R. F., and Evans, M. C. (2004) Wound healing: an overview of acute, fibrotic and delayed healing. Front. Biosci. 9, 285–299
4. Koh, T. J., and DiPietro, L. A. (2011) Inflammation and wound healing: the role of the macrophage. Expert Rev. Mol. Med. 13, e23
Graf, C., Kovina, P., and Bornancin, F. (2009) A secondary assay for ceramide kinase inhibitors based on cell growth inhibition by short-chain ceramides. Anal. Biochem. 384, 166–169

Pettus, B. J., Bielawski, J., Porcelli, A. M., Reames, D. L., Johnson, K. R., Morrow, J., Chaffant, C. E., Obeid, L. M., and Hannun, Y. A. (2009) The sphingosine kinase 1/sphingosine-1-phosphate pathway mediates COX-2 induction and PGE2 production in response to TNF-α. FASEB J. 17, 1411–1421

Slon-Usakiewicz, J. J., Dai, J.-R., Ng, W., Foster, J. E., Deretey, E., Katz, S., Ernst, O., Avni, D., Athamna, M., Philosoph, A., Arana, L., Simanshu, D. K., Kamlekar, R. K., Wijesinghe, D. S., Zou, X., Zhai, M., Mishra, S. K., Gao, Y.-G., Zou, X., Stephenson, D. J., Malinina, L., Konya, V., Bl...}

Bionda, C., Portoukalian, J., Schmitt, D., Rodriguez-Lafresse, C., and Ardaill, D. (2004) Subcellular compartmentalization of ceramide metabolism: MAM (mitochondria-associated membrane) and/or mitochondria? Biochem. J. 382, 527–533

Lai, Q., Yuan, G., Shen, L., Zhang, L., Fu, F., Liu, Z., Zhang, Y., Wang, Y., Liu, S., Li, B., and Li, F. (2014) Oxioeicinoid receptor inhibition alleviates acute myocardial infarction through activation of BATC. Basic Res. Cardiol. 110, 3

Cooke, M., Di Consoli, H., Malolberi, P., and Maciel, F. C. (2013) Expression and function of OXE receptor, an eicosanoid receptor, in stereoidogenic cells. Mol. Cell. Endocrinol. 371, 77–88

Feingold, K. R., Moser, A., Shigenaga, J. K., and Grunfeld, C. (2014) Inflammation stimulates niacin receptor (GPR109A/HCA2) expression in adipose tissue and macrophages. J. Lipid Res. 55, 2501–2508

Stephenson, D. J., Hoeferlin, L. A., and Chaffant, C. E. (2017) Lipidomics in translational research and the clinical significance of Chan-based markers. Transl. Res. 189, 13–26

Olto, T., Uozumi, N., Hiraibayashi, T., and Shimizu, T. (2005) Identification of novel cytosolic phospholipase A2s, murine cPLA2-α, β, and ε, which form a gene cluster with cPLA2-β. J. Biol. Chem. 280, 24576–24583

Ghomashchi, F., Naika, G. S., Bollinger, J. G., Aloulou, A., Lehr, M., Leslie, C. C., and Gelb, M. H. (2015) Interfacial kinetic and binding properties of mammalian group IVB phospholipase A2 family members in the regulation of autophagy, inflammation, and/or mitochondria? Biochem. J. 465, 329–347

Granozio, M. G., Chaffant, C. E., and Brown, R. E. (2020) Emerging roles for human glycolipid transfer protein super-family members in the regulation of autophagy, inflammation, and cell death. Prog. Lipid Res. 78, 101031

Lamour, N. F., Slack, K. V., Apelgethe, D. S., Macevka, M., Wang, E., Allegro, J., Mertin, A. H., Jr, Cho, W., and Chaffant, C. E. (2007) Ceramide kinase uses ceramide provided by ceramide transfer protein: localization to organelles of eicosanoid synthesis. J. Lipid Res. 48, 1293–1304

Simanshu, D. K., Kamlekar, R. K., Wijesinghe, D. S., Zou, X., Zhai, X., Mishra, S. K., Grunfeld, C., and Gelb, M. H. (2005) Oxioeicinoid receptor inhibition by short-chain ceramides promotes cell migration: involvement of a specific C1P analogue-1 (PCERA-1) and phospho-ceramide analogue-1 (PCERA-1) regulate eicosanoids. Nature 430, 465–468

Mishra, S. K., Gao, Y.-G., Deng, Y., Chaffant, C. E., Hinchcliffe, E. H., and Brown, R. E. (2018) CPTP: a sphingolipid transfer protein that regulates autophagy and inflammation activation. Autophagy 14, 862–879

Parekh, A., Sandulache, V. C., Singh, T., Cetin, S., Sacks, M. S., Dohar, J. E., and Hebda, P. A. (2009) Prostaglandin E2 differentially regulates contractile and structural reorganization of anchored collagen gels by human adult and fetal dermal fibroblasts. Wound Repair Regen. 17, 88–98

Kim, M.-H., Liu, W., Borjeson, D. L., Curry, F. R., Miller, L. S., Cheung, A. L., Liu, F.-T., Isseoff, R. R., and Simon, S. I. (2008) Dynamics of neutrophil infiltration during cutaneous wound healing and infection using fluorescence imaging. J. Invest. Dermatol. 128, 1812–1820

Truett III, A. P., and King, L. E., Jr. (1993) Sphingomyelinase D: a pathogenic agent produced by bacteria and arthropods. Adv. Lipid Res. 26, 275–291

Rees, R. S., Nanney, L. B., Yates, R. A., and King, L. E., Jr. (1984) Interaction of brown recluse spider venom on cell membranes: the inciting mechanism? J. Invest. Dermatol. 83, 270–275

Pettus, B. J., Kitatani, K., Chaffant, C. E., Taha, T. A., Kawamori, T., Bielawski, J., Obeid, L. M., and Hannun, Y. A. (2005) The coordination of prostaglandin E2 production by sphingosine-1-phosphate and ceramide-1-phosphate. Mol. Pharmacol. 68, 225–233

Mariutti, R. B., Claves-Moreira, D., Vuitita, L., Caruso, I. P., Coronado, M. A., Azevedo, V. A., Murakami, M. T., Veiga, S. G., and Arni, R. K. (2017) Bacterial and arachnid sphingomyelinases D: comparison of biophysical and pathological activities. J. Cell. Biochem. 118, 2053–2063

Tobon, C. L., Galvez, S., Canelo, R. S., Martin, S. O., Ghahrai, N. N., Golome, P. M., Fullerton, M. S., Conrad, D. H., Chaffant, C. E., Voth, D. E., Rucks, F. A., Gilk, S. D., and Carlyon, J. A. (2019) Functional inhibition of acid sphingomyelinase disrupts infection by intracellular bacterial pathogens. Life Sci. Alliance. 2, e201800292

Walsh, S. W., Reep, D. T., Alam, S. M. K., Washington, S. L., Al-Dair, D., and Chalfant, C. E., Ma, J-X., and Karamichos, D. (2016) Complete metabolome and lipidome analysis reveals novel biomarkers in the human diabetic corneal stroma. Exp. Eye Res. 153, 90–100

Van Overloop, H., Van der Hoeven, G., and Van Veldhoven, P. P. (2014) Targeting ceramide metabolism with inhibitors of Ceramide kinase inhibitors using a homogeneous chemiluminescence assay. Drug Disc. Today. 19, 2169–2175

Nelson, A. J., Shaptop, D. J., Bone, R. N., Cardona, C. L., Park, M. A., Tsing, Y. G., Lei, X., Kokotos, G., Graves, C. L., Mathews, C. C., Kraner, J., Hesner, J., Chaffant, C. E., and Ramanathan, S. (2020) Lipid mediators and biomarkers associated with type 1 diabetes development. JCI Insight. 5, e138034

Priyadarshini, S., McKay, T. B., Sarker-Nag, A., Allegro, J., Chaffant, C. E., Ma, J-X., and Karamichos, D. (2016) Complete metabolome and lipidome analysis reveals novel biomarkers in the human diabetic corneal stroma. Exp. Eye Res. 153, 90–100

Graf, C., Kupp, M., Habiag, M., Rovina, P., Billich, A., Baumgarten, T., Oberhauser, B., and Bornancin, F. (2008) Targeting ceramide metabolism with a potent and specific ceramide kinase inhibitor. Mol. Pharmacol. 74, 925–932

Wells, C. L., Al-Ali, H., Andrews, D. M., Asseff, C. R. M., Axtman, A. D., Dikie, L. Eiber, D., Ettema, P. Fischer, C., Frederiksen, M., Futrell, R. E., Gray, N. S., Hatch, S. B., Knapp, S., Lücking, U., et al. (2021) The kinase chemogenetic system (KCGS): an open source resource for kinase vulnerability identification. Int. J. Mol. Sci. 22, 506

Sun, N. T., Park, M. A., Schulz, M. D., Gamze, B. B., Ladd, A. C., and Chaffant, C. E. (2016) Gaspase-9b interacts directly with Chaperin PIP to drive agonist-independent activation of NF-kB and lung tumorigenesis. Cancer Res. 76, 2977–2989
77. Goehe, R. W., Shultz, J. C., Murudkar, C., Usanovic, S., Lamour, N. F., Massey, D. H., Zhang, L., Camidge, D. R., Shay, J. W., Minna, J. D., and Chalfant, C. E. (2010) hnRNP L regulates the tumorigenic capacity of lung cancer xenografts in mice via caspase-9 premRNA processing. J. Clin. Invest. 120, 3923–3939

78. Shultz, J. C., Goehe, R. W., Wijesinghe, D. S., Murudkar, C., Hawkins, A. J., Shay, J. W., Minna, J. D., and Chalfant, C. E. (2010) Alternative splicing of caspase 9 is modulated by the phosphoinositide 3-kinase/Akt pathway via phosphorylation of SRp30a. Cancer Res. 70, 9185–9196

79. Shultz, J. C., Goehe, R. W., Murudkar, C. S., Wijesinghe, D. S., Mayton, E. K., Massiello, A., Hawkins, A. J., Mukerjee, P., Pinkerman, R. L., Park, M. A., and Chalfant, C. E. (2011) SRSF1 regulates the alternative splicing of caspase 9 via a novel intronic splicing enhancer affecting the chemotherapeutic sensitivity of non-small cell lung cancer cells. Mol. Cancer Res. 9, 889–900

80. Vu, N., Park, M., Shultz, J., Goehe, R., Hoeferlin, L. A., Shultz, M., Smith, S., Lynch, K., and Chalfant, C. (2013) hnRNP U enhances caspase-9 splicing and is modulated by AKT-dependent phosphorylation of hnRNP L. J. Biol. Chem. 288, 8575–8584